Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 8:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 11,562 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: CHRONIC DISEASE Clear all
Completed Phase 3 Interventional Results available

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

NCT03448406
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
43
States / cities
Mobile, Alabama • Saraland, Alabama • Huntington Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 31, 2026, 8:41 PM EDT
Terminated No phase listed Observational

Impact of CTO PCI (Chronic Total Occlusion Percutaneous Intervention) on Regular Physical Activity

NCT05440084
View directory record Official record
Conditions
Chronic Total Occlusion, Occlusion
Interventions
Chronic total occlusion percutaneous coronary intervention
Procedure
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 31, 2026, 8:41 PM EDT
Completed Not applicable Interventional

The Impact of Co-Dispensing Naloxone to Patients Prescribed Chronic Opioid Therapy

NCT03337100
View directory record Official record
Conditions
Overdose, Risk Behavior
Interventions
Co-Dispensing
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 31, 2026, 8:41 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

LungVITamin D and OmegA-3 Trial (lungVITAL)

NCT01728571
View directory record Official record
Conditions
COPD, Asthma, Pulmonary Function, Pneumonia
Interventions
Vitamin D3, fish oil, Vitamin D3 placebo, Fish oil placebo
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 31, 2026, 8:41 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Palliative Care Health Literacy Education and QOL Compared to Usual Care

NCT06089499
View directory record Official record
Conditions
COPD
Interventions
Get Palliative Care: four educational learning module videos
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 31, 2026, 8:41 PM EDT
Completed Not applicable Interventional

Nutrient Levels Alter Transplant Outcome

NCT00560014
View directory record Official record
Conditions
Chronic Renal Disease
Interventions
Arginine and canola oil, Coromega and Arginine
Dietary Supplement
Lead sponsor
University of Cincinnati
Other
Eligibility
Not listed
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2007 · Synced Oct 31, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors

NCT00093821
View directory record Official record
Conditions
Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor, Disseminated Neuroblastoma, Metastatic Childhood Soft Tissue Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma
Interventions
tanespimycin, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 31, 2026, 8:41 PM EDT
Terminated Phase 3 Interventional Results available

Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System

NCT01011816
View directory record Official record
Conditions
Back Pain, Chronic Low Back Pain, Internal Disc Disruption, Degenerative Disc Disease
Interventions
BIOSTAT BIOLOGX, Saline
Biological · Drug
Lead sponsor
Spinal Restoration, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 31, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function

NCT02678000
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
LHW090, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Anaheim, California • Lakewood, Colorado • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 31, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors

NCT00003269
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, amifostine trihydrate, cisplatin, cyclophosphamide, etoposide
Biological · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Oct 31, 2026, 8:41 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Active and Healthy Brotherhood: A Program for Chronic Disease Self-Management for Black Men

NCT02362737
View directory record Official record
Conditions
Chronic Disease, Obesity, Hypertension, Diabetes, Self Care, Medication Adherence
Interventions
Active and Healthy Brotherhood (AHB)
Behavioral
Lead sponsor
Gramercy Research Group
Other
Eligibility
21 Years to 64 Years · Male only
Enrollment
332 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 31, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia

NCT00004245
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
sodium salicylate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 31, 2026, 8:41 PM EDT
Completed Not applicable Interventional

Electrical Stimulation and a Dynamic Orthosis for Stroke Recovery

NCT02887872
View directory record Official record
Conditions
Stroke
Interventions
Electrical stimulation-dynamic hand orthosis
Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
20 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 31, 2026, 8:41 PM EDT
Completed Phase 1Phase 2 Interventional

Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate

NCT00093639
View directory record Official record
Conditions
Leukemia
Interventions
everolimus, imatinib mesylate
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 31, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

NCT03133221
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma, B-cell Lymphoma, Transformed Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma
Interventions
Zydelig
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Miami, Florida • Baltimore, Maryland • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 31, 2026, 8:41 PM EDT
Completed Not applicable Interventional

REST: Restoring Effective Sleep Tranquility in College Veterans With Service-Related Injuries

NCT02871414
View directory record Official record
Conditions
Chronic Insomnia
Interventions
REST - Early Group, REST - Late Group
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 31, 2026, 8:41 PM EDT
Completed Not applicable Interventional

Effect of Exercise on Endothelial Function and Vascular Compliance in Chronic Kidney Disease

NCT01068314
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Repetitive arm exercise
Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 31, 2026, 8:41 PM EDT
Terminated Phase 2 Interventional

Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes

NCT00104806
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cholecalciferol, arsenic trioxide
Dietary Supplement · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 120 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 31, 2026, 8:41 PM EDT
Recruiting Not applicable Interventional

Non-invasive VNS in Stroke Recovery

NCT06761404
View directory record Official record
Conditions
Stroke
Interventions
taVNS
Device
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 31, 2026, 8:41 PM EDT
Terminated Phase 2 Interventional Results available

A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough

NCT03979638
View directory record Official record
Conditions
Chronic Refractory Cough
Interventions
BLU-5937, Placebo
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
San Diego, California • San Jose, California • Largo, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 31, 2026, 8:41 PM EDT
Completed Not applicable Interventional

Chronic Pain Diagnosis and Treatment in Torture Survivors

NCT04629963
View directory record Official record
Conditions
Pain, Pain, Chronic
Interventions
Pain Evaluation and BPISF, Surveys, a fingerstick blood sample, EMAs, and a digital wearable device
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 31, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant

NCT01812252
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome
Interventions
Azacitidine (AZC), Decitabine, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
4
States / cities
Scottsdale, Arizona • Cleveland, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 31, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

NCT02349048
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Bakersfield, California • Jacksonville, Florida • Lutherville, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 31, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents

NCT00003635
View directory record Official record
Conditions
Leukemia
Interventions
nelarabine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 31, 2026, 8:41 PM EDT